Literature DB >> 21994110

Prospective assessment of pain and functional status after vertebroplasty for treatment of vertebral compression fractures.

A J Evans1, K E Kip, S M Boutin.   

Abstract

BACKGROUND AND
PURPOSE: There has been no prospective evaluation of vertebroplasty using a validated instrument. We describe the pain and functional status of 72 patients before and after vertebroplasty, as prospectively evaluated by the Vertebral Compression Fracture Pain and Functional Disability Questionnaire.
METHODS: Of 161 consecutive patients, 72 consented to participate in the study and self-completed the questionnaire prior to undergoing vertebroplasty. Differences in pain and distress before and after vertebroplasty, and between the first and second follow-up intervals, were evaluated. Mean scores for each of 24 activities of daily living (ADLs) were plotted at the baseline and first and second follow-up intervals.
RESULTS: The mean (SD) patient age was 74 (10) years; 80% were female. On the 0 (no pain) to 10 (pain as bad as it could be) visual analog pain scale, patients reported significantly more pain, on average, before undergoing percutaneous vertebroplasty (PV) than at the first follow-up interval (mean 5.8 vs 3.5, p<0.001). The reduction in reported pain following vertebroplasty persisted at the second follow-up on both the visual analog and adjectival pain scales. Among the 24 ADLs, between 25% and 69% of patients reported a mean improvement of at least 1 level on the 5-point ADL scale, and between 14% and 55% reported a mean improvement of at least two levels. The majority of the improvement in reported functional status following vertebroplasty was sustained at the second follow-up interval.
CONCLUSION: PV resulted in substantial, lasting reduction in pain and improvement in ability to perform ADLs.

Entities:  

Mesh:

Year:  2009        PMID: 21994110     DOI: 10.1136/jnis.2009.000158

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836



北京卡尤迪生物科技股份有限公司 © 2022-2023.